Clinical Trials Browser

decitabine and cedazuridine drug combination × Breast × 90 days × Clear all

NCT05673200 2026-05-13

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Phase 1 Recruiting

Triple Negative Breast Neoplasms